FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011617> ?p ?o ?g. }

• W4377011617 endingPage "e45502" @default.
• W4377011617 startingPage "e45502" @default.
• W4377011617 abstract "Compared with adults with normal glucose metabolism, those with prediabetes tend to be frail. However, it remains poorly understood whether frailty could identify adults who are most at risk of adverse outcomes related to prediabetes.We aimed to systematically evaluate the associations between frailty, a simple health indicator, and risks of multiple adverse outcomes including incident type 2 diabetes mellitus (T2DM), diabetes-related microvascular disease, cardiovascular disease (CVD), chronic kidney disease (CKD), eye disease, dementia, depression, and all-cause mortality in late life among middle-aged adults with prediabetes.We evaluated 38,950 adults aged 40 years to 64 years with prediabetes using the baseline survey from the UK Biobank. Frailty was assessed using the frailty phenotype (FP; range 0-5), and participants were grouped into nonfrail (FP=0), prefrail (1≤FP≤2), and frail (FP≥3). Multiple adverse outcomes (ie, T2DM, diabetes-related microvascular disease, CVD, CKD, eye disease, dementia, depression, and all-cause mortality) were ascertained during a median follow-up of 12 years. Cox proportional hazards regression models were used to estimate the associations. Several sensitivity analyses were performed to test the robustness of the results.At baseline, 49.1% (19,122/38,950) and 5.9% (2289/38,950) of adults with prediabetes were identified as prefrail and frail, respectively. Both prefrailty and frailty were associated with higher risks of multiple adverse outcomes in adults with prediabetes (P for trend <.001). For instance, compared with their nonfrail counterparts, frail participants with prediabetes had a significantly higher risk (P<.001) of T2DM (hazard ratio [HR]=1.73, 95% CI 1.55-1.92), diabetes-related microvascular disease (HR=1.89, 95% CI 1.64-2.18), CVD (HR=1.66, 95% CI 1.44-1.91), CKD (HR=1.76, 95% CI 1.45-2.13), eye disease (HR=1.31, 95% CI 1.14-1.51), dementia (HR=2.03, 95% CI 1.33-3.09), depression (HR=3.01, 95% CI 2.47-3.67), and all-cause mortality (HR=1.81, 95% CI 1.51-2.16) in the multivariable-adjusted models. Furthermore, with each 1-point increase in FP score, the risk of these adverse outcomes increased by 10% to 42%. Robust results were generally observed in sensitivity analyses.In UK Biobank participants with prediabetes, both prefrailty and frailty are significantly associated with higher risks of multiple adverse outcomes, including T2DM, diabetes-related diseases, and all-cause mortality. Our findings suggest that frailty assessment should be incorporated into routine care for middle-aged adults with prediabetes, to improve the allocation of health care resources and reduce diabetes-related burden." @default.
• W4377011617 created "2023-05-19" @default.
• W4377011617 creator A5005411410 @default.
• W4377011617 creator A5012013762 @default.
• W4377011617 creator A5013453597 @default.
• W4377011617 creator A5015894529 @default.
• W4377011617 creator A5017585651 @default.
• W4377011617 creator A5035221383 @default.
• W4377011617 creator A5035548519 @default.
• W4377011617 creator A5035791019 @default.
• W4377011617 creator A5042844118 @default.
• W4377011617 creator A5049259539 @default.
• W4377011617 creator A5052170982 @default.
• W4377011617 creator A5053943936 @default.
• W4377011617 creator A5066652972 @default.
• W4377011617 date "2023-05-18" @default.
• W4377011617 modified "2023-10-04" @default.
• W4377011617 title "Associations Between Frailty and the Increased Risk of Adverse Outcomes Among 38,950 UK Biobank Participants With Prediabetes: Prospective Cohort Study" @default.
• W4377011617 cites W1511593276 @default.
• W4377011617 cites W2003416763 @default.
• W4377011617 cites W2082704080 @default.
• W4377011617 cites W2107797783 @default.
• W4377011617 cites W2115098571 @default.
• W4377011617 cites W2130474358 @default.
• W4377011617 cites W2164059021 @default.
• W4377011617 cites W2332951586 @default.
• W4377011617 cites W2512088356 @default.
• W4377011617 cites W2512690207 @default.
• W4377011617 cites W2527103698 @default.
• W4377011617 cites W2586433967 @default.
• W4377011617 cites W2598826230 @default.
• W4377011617 cites W2601221505 @default.
• W4377011617 cites W2795268887 @default.
• W4377011617 cites W2796661030 @default.
• W4377011617 cites W2807745201 @default.
• W4377011617 cites W2889526011 @default.
• W4377011617 cites W2892396086 @default.
• W4377011617 cites W2903235642 @default.
• W4377011617 cites W2912010294 @default.
• W4377011617 cites W2916803190 @default.
• W4377011617 cites W2946423972 @default.
• W4377011617 cites W2971121994 @default.
• W4377011617 cites W2984824576 @default.
• W4377011617 cites W2992031216 @default.
• W4377011617 cites W2996959176 @default.
• W4377011617 cites W3019819223 @default.
• W4377011617 cites W3043916132 @default.
• W4377011617 cites W3093385449 @default.
• W4377011617 cites W3110280394 @default.
• W4377011617 cites W3126197040 @default.
• W4377011617 cites W3129035091 @default.
• W4377011617 cites W3158937424 @default.
• W4377011617 cites W3164312453 @default.
• W4377011617 cites W3201057215 @default.
• W4377011617 cites W3206576542 @default.
• W4377011617 cites W3210126550 @default.
• W4377011617 cites W4224219026 @default.
• W4377011617 cites W4308463484 @default.
• W4377011617 cites W4311263986 @default.
• W4377011617 cites W49712109 @default.
• W4377011617 doi "https://doi.org/10.2196/45502" @default.
• W4377011617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37200070" @default.
• W4377011617 hasPublicationYear "2023" @default.
• W4377011617 type Work @default.
• W4377011617 citedByCount "1" @default.
• W4377011617 crossrefType "journal-article" @default.
• W4377011617 hasAuthorship W4377011617A5005411410 @default.
• W4377011617 hasAuthorship W4377011617A5012013762 @default.
• W4377011617 hasAuthorship W4377011617A5013453597 @default.
• W4377011617 hasAuthorship W4377011617A5015894529 @default.
• W4377011617 hasAuthorship W4377011617A5017585651 @default.
• W4377011617 hasAuthorship W4377011617A5035221383 @default.
• W4377011617 hasAuthorship W4377011617A5035548519 @default.
• W4377011617 hasAuthorship W4377011617A5035791019 @default.
• W4377011617 hasAuthorship W4377011617A5042844118 @default.
• W4377011617 hasAuthorship W4377011617A5049259539 @default.
• W4377011617 hasAuthorship W4377011617A5052170982 @default.
• W4377011617 hasAuthorship W4377011617A5053943936 @default.
• W4377011617 hasAuthorship W4377011617A5066652972 @default.
• W4377011617 hasBestOaLocation W43770116171 @default.
• W4377011617 hasConcept C126322002 @default.
• W4377011617 hasConcept C134018914 @default.
• W4377011617 hasConcept C188816634 @default.
• W4377011617 hasConcept C201903717 @default.
• W4377011617 hasConcept C207103383 @default.
• W4377011617 hasConcept C2777180221 @default.
• W4377011617 hasConcept C2779134260 @default.
• W4377011617 hasConcept C2779483572 @default.
• W4377011617 hasConcept C2779668308 @default.
• W4377011617 hasConcept C44249647 @default.
• W4377011617 hasConcept C555293320 @default.
• W4377011617 hasConcept C71924100 @default.
• W4377011617 hasConcept C72563966 @default.
• W4377011617 hasConcept C74909509 @default.
• W4377011617 hasConceptScore W4377011617C126322002 @default.
• W4377011617 hasConceptScore W4377011617C134018914 @default.
• W4377011617 hasConceptScore W4377011617C188816634 @default.
• W4377011617 hasConceptScore W4377011617C201903717 @default.

• next